-
PD 173074: FGFR1 and VEGFR2 Research Guide
2026-09-21
PD 173074 is an ATP-competitive FGFR1 and VEGFR2 inhibitor used to study FGFR signaling pathway inhibition, angiogenesis, and cancer research. Its strongest evidence supports biochemical kinase inhibition and preclinical pathway interrogation, not established clinical efficacy.
-
Pifithrin-α: Translating p53 Insight into Protection
2026-09-21
Pifithrin-α (PFTα) is more than a conventional p53 inhibitor: it is a mechanistic probe for separating p53-driven apoptosis, ferroptosis, and cell-cycle responses. This article connects recent neurotoxicology findings with translational strategies for radiation biology, neuroprotection, and cancer therapy side effect mitigation.
-
Oligo (dT) 25 Beads for Immune RNA Insight
2026-09-20
Oligo (dT) 25 Beads provide selective polyA tail mRNA capture for clean, adaptable transcript workflows. This article explains how magnetic enrichment can support immune-aging studies while preserving the distinctions between bulk mRNA assays and single-cell RNA sequencing.
-
Dextrose (D-glucose) for Reliable Cell Assays
2026-09-19
This scenario-based guide explains how Dextrose (D-glucose), SKU A8406, can improve control of glucose-dependent variables in cell viability, proliferation, cytotoxicity, and immunometabolism workflows. It combines practical concentration planning, solution-handling guidance, data interpretation, and evidence from recent tumor hypoxia research.
-
Lamotrigine Research Workflows for Ion Channels
2026-09-18
Build reproducible Lamotrigine assays for neuronal sodium-channel studies, serotonin pathway experiments, and cardiac electrophysiology. This guide combines solubility-aware dosing with an HPLC-MS-inspired workflow that helps distinguish direct pharmacology from compound handling artifacts.
-
WP1066: Contextual Control of JAK2/STAT3
2026-09-18
WP1066, a cell-permeable JAK2/STAT3 inhibitor, can reveal whether pathway activity is causally required in cancer and macrophage-centered repair models. This guide connects mechanistic pharmacology with assay design while clarifying why pathway inhibition and activation must not be conflated.
-
Bazedoxifene Repurposing for Antimalarial Research
2026-09-17
Sudhakar et al. show that bazedoxifene, a selective estrogen receptor modulator used in postmenopausal osteoporosis, inhibits erythrocytic Plasmodium development and disrupts hemozoin formation. The study supports a mechanistically informed repurposing strategy while highlighting parasite stage, host sex, and model selection as important variables for translation.
-
Dextrose for Tumor Immunometabolism Workflows
2026-09-17
Build controlled glucose gradients, hypoxia models, and immune–tumor co-cultures with Dextrose (D-glucose) as an adjustable metabolic input. This workflow-focused guide connects reagent handling with assay design, troubleshooting, and practical interpretation of nutrient competition in the tumor microenvironment.
-
4-Methoxychalcone-1 in Secretory Cell Research
2026-09-16
Explore how 4-Methoxychalcone-1 can be evaluated as an exploratory chemical perturbation in single-cell secretion studies. This article connects compound testing with SEC-seq, showing why secretion measurements and transcriptomic state should be interpreted together.
-
Amikacin (BAY416651): A New Lens on Resistance
2026-09-16
Carbapenem resistance is not only a susceptibility problem; it is a problem of gene location, mobility, expression, and phenotype. This thought-leadership article positions Amikacin (BAY416651) as a mechanistically informative bacterial protein synthesis inhibitor for connecting ribosomal activity with aminoglycoside resistance, plasmid transmission, and translational surveillance in high-priority Enterobacterales.
-
Dextrose (D-Glucose) for Immunometabolic Assays
2026-09-15
Discover how Dextrose (D-glucose) can be used as a controlled metabolic input in hypoxia and tumor–immune co-culture assays. This guide translates recent immunometabolism findings into practical choices for substrate controls, assay interpretation, and reproducible glucose metabolism research.
-
3-Aminobenzamide: PARP-IN-1 Research Workflows
2026-09-15
3-Aminobenzamide (PARP-IN-1) provides a practical chemical entry point for studying poly (ADP-ribose) polymerase inhibition in oxidative-stress, vascular, renal, and host–pathogen models. This guide connects dose-ranging, functional endpoints, and reference-informed controls to help distinguish genuine pathway modulation from vehicle effects, cytotoxicity, or assay drift.
-
TaqI Restriction Endonuclease Protocol
2026-09-14
TaqI Restriction Endonuclease provides sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA when a target TCG A recognition site is present. It is intended for rapid research workflows and DNA manipulation, but should not be used for diagnostic, clinical, or medical applications.
-
Nullscript and the Translational Logic of HDAC Inhibition
2026-09-14
Nullscript offers a mechanistically useful way to study histone deacetylase biology without assuming that every HDAC-linked phenotype is caused by transcriptional facilitation. This thought-leadership analysis connects its cardiac ischemia/reperfusion evidence with emerging metabolic and ferroptotic mechanisms in placental nanoplastic toxicity while clearly separating established findings from translational hypotheses.
-
RHO P347L Retinitis Pigmentosa: Endocytosis and Stress
2026-09-13
This 2026 study distinguishes the cellular mechanisms of severe RHO P347L retinitis pigmentosa from those of the milder Class 2 L125R variant. By combining knock-in mouse models, retinal phenotyping, transcriptomics, and trafficking assays, it identifies enhanced rhodopsin endocytosis, lysosomal burden, and mitochondrial dysfunction as major features of P347L disease.